Results 71 to 80 of about 209,258 (305)

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. [PDF]

, 2018
Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly because of dynamic changes in cellular signaling that drive resistance ...
A Bosch, A Katsha, A Subramanian, AA Dar, Andrei Goga, AS Nikonova, AV Statsuk, AY Choo, B MacLean, C Leroy, Cancer Genome Atlas Network., D Bankston, DA Fruman, F Janku, F Zheng, GR Anderson, H Daub, H Yang, Hayley J. Donnella, J Baselga, J Foucquier, J Hollander den, J Lehár, JA Diehl, James E. Korkola, James T. Webber, JE Ferrell Jr., JF Blake, John D. Gordan, JS Duncan, KE O’Reilly, Kevan M. Shokat, Khyati N. Shah, KJ Brewer Savannah, L Boussemart, L Lu, L Vadlakonda, LL Liu, M Bantscheff, M Barvian, M Choi, M Elkabets, M Laplante, M Piccart, M Tanaka, MJ West, MK Muellner, ML Sos, MM Martins, N Dey, N Ilic, N Volkmann, Nora Bayani, Olga Momcilovic, P Liu, PM Barr, PP Roux, QB She, R Sears, RB Corcoran, Rebecca S. Levin, RM Neve, Roman Camarda, SJ Klempner, SMA Lens, Sourav Bandyopadhyay, SR Vora, TJ Stuhlmiller, TK Nomanbhoy, Y Zwang   +69 more
core   +1 more source

Integrated genomic and proteomic profiling reveals insights into chemoradiation resistance in cervical cancer

Molecular Oncology, EarlyView.
A comprehensive genomic and proteomic analysis of cervical cancer revealed STK11 and STX3 as a potential biomarkers of chemoradiation resistance. Our study demonstrated EGFR as a therapeutic target, paving the way for precision strategies to overcome treatment failure and the DNA repair pathway as a critical mechanism of resistance.
Janani Sambath, Irene A. George, Srikanth S. Manda, Prasanth Ariyannur, Ekta R. Dhawale, Raja Sekhar Kommu, Rajan Datar, Darshana Patil, Vinita Trivedi, Manisha Singh, Kumar Prabhash, Sewanti Limaye, Richa Chauhan, Prashant Kumar   +13 more
wiley   +1 more source

Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome [PDF]

, 2017
Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.
Cannoodt, Robrecht, Claeys, Shana, De Preter, Katleen, Denecker, Geertrui, Durinck, Kaat, Kumps, Candy, Speleman, Franki   +6 more
core   +3 more sources

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

Oncotarget, 2014
We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycin-sensitive were sensitive to MLN0128 in vitro.
Burhan, Hassan, Argun, Akcakanat, Takafumi, Sangai, Kurt W, Evans, Farrell, Adkins, Agda Karina, Eterovic, Hao, Zhao, Ken, Chen, Huiqin, Chen, Kim-Anh, Do, Shelly M, Xie, Ashley M, Holder, Aung, Naing, Gordon B, Mills, Funda, Meric-Bernstam   +14 more
openaire   +3 more sources

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Investigating the effect of target of rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets [PDF]

, 2019
Recuperado de: https://www.biorxiv.org/content/10.1101/310102v1Target of rapamycin (TOR) kinase is a conserved regulator of cell growth whose activity is modulated in response to nutrients, energy and stress.
Couso Liáñez, Inmaculada Concepción, Crespo González, José Luis, Hicks, Leslie, McConnell, Evan W., Perrine, Zoee, Umen, James G., Werth, Emily G.   +6 more
core   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Liver transplantation [PDF]

, 2014
Purpose of review: Long-term survival of liver transplant recipients is threatened by increased rates of de-novo malignancy and recurrence of hepatocellular carcinoma (HCC), both events tightly related to immunosuppression.
Burroughs, AK, De la Mata, M, Rodríguez-Perálvarez, M   +2 more
core  

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Systemic Therapy in Endometrial Cancer: Recent Advances. [PDF]

, 2013
Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well.
Bhise, R, Guru Prasad B, B, Kundargi, R, Lakshmaia, KC, Purohit, S, Shetty, R   +5 more
core   +1 more source